Welcome to LookChem.com Sign In|Join Free

CAS

  • or

872141-30-5

7'-fluoro-Spiro[cyclopropane-1,3'-[3H]indol]-2'(1'H)-one is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

872141-30-5 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 872141-30-5 Structure

  • Basic information

    1. Product Name: 7'-fluoro-Spiro[cyclopropane-1,3'-[3H]indol]-2'(1'H)-one
    2. Synonyms: 7'-fluoro-Spiro[cyclopropane-1,3'-[3H]indol]-2'(1'H)-one;7'-Fluoro-1'H-spiro[cyclopropane-1,3'-indole]-2'-one;7-fluorospiro[cyclopropane-1,3-indoline]-2-one;7-FLUOROSPIRO[CYCLOPROPANE-1,3-INDOLIN]-2-ONE
    3. CAS NO:872141-30-5
    4. Molecular Formula: C10H8FNO
    5. Molecular Weight: 177.1750232
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 872141-30-5.mol

  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: /
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: 7'-fluoro-Spiro[cyclopropane-1,3'-[3H]indol]-2'(1'H)-one(CAS DataBase Reference)
    10. NIST Chemistry Reference: 7'-fluoro-Spiro[cyclopropane-1,3'-[3H]indol]-2'(1'H)-one(872141-30-5)
    11. EPA Substance Registry System: 7'-fluoro-Spiro[cyclopropane-1,3'-[3H]indol]-2'(1'H)-one(872141-30-5)

  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 872141-30-5(Hazardous Substances Data)

872141-30-5 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 872141-30-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,2,1,4 and 1 respectively; the second part has 2 digits, 3 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 872141-30:
(8*8)+(7*7)+(6*2)+(5*1)+(4*4)+(3*1)+(2*3)+(1*0)=155
155 % 10 = 5
So 872141-30-5 is a valid CAS Registry Number.

872141-30-5Downstream Products

872141-30-5Relevant articles and documents

Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion

Cockerill, G. Stuart,Angell, Richard M.,Bedernjak, Alexandre,Chuckowree, Irina,Fraser, Ian,Gascon-Simorte, Jose,Gilman, Morgan S. A.,Good, James A. D.,Harland, Rachel,Johnson, Sara M.,Ludes-Meyers, John H,Littler, Edward,Lumley, James,Lunn, Graham,Mathews, Neil,McLellan, Jason S.,Paradowski, Michael,Peeples, Mark E.,Scott, Claire,Tait, Dereck,Taylor, Geraldine,Thom, Michelle,Thomas, Elaine,Villalonga Barber, Carol,Ward, Simon E.,Watterson, Daniel,Williams, Gareth,Young, Paul,Powell, Kenneth

supporting information, p. 3658 - 3676 (2021/04/12)

RV521 is an orally bioavailable inhibitor of respiratory syncytial virus (RSV) fusion that was identified after a lead optimization process based upon hits that originated from a physical property directed hit profiling exercise at Reviral. This exercise encompassed collaborations with a number of contract organizations with collaborative medicinal chemistry and virology during the optimization phase in addition to those utilized as the compound proceeded through preclinical and clinical evaluation. RV521 exhibited a mean IC50 of 1.2 nM against a panel of RSV A and B laboratory strains and clinical isolates with antiviral efficacy in the Balb/C mouse model of RSV infection. Oral bioavailability in preclinical species ranged from 42 to >100% with evidence of highly efficient penetration into lung tissue. In healthy adult human volunteers experimentally infected with RSV, a potent antiviral effect was observed with a significant reduction in viral load and symptoms compared to placebo.

Progesterone receptor antagonists, contraceptive regimens, and kits

-

Page/Page column 10, (2010/02/15)

A method of contraception is provided which involves delivery of 21 to 27 consecutive days of one or more PR antagonists in the absence of a progestin, estrogen, or other steroidal compound, followed by 1 to 7 days without any active agent. Also described is a pharmaceutically useful kit to facilitate delivery of this regimen.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 872141-30-5